key: cord-0701700-nqcxq0jc
authors: Yeshurun, Moshe; Pasvolsky, Oren; Shargian, Liat; Yahav, Dafna; Ben-Zvi, Haim; Rubinstein, Maly; Sela-Navon, Michal; Wolach, Ofir; Raanani, Pia; Rozovski, Uri
title: Humoral serologic response to the BNT162b2 vaccine after allogeneic haematopoietic cell transplantation
date: 2021-10-29
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2021.10.007
sha: 48681fd3b255663ec39d3b080cc0d85ef04e8464
doc_id: 701700
cord_uid: nqcxq0jc

OBJECTIVES: Assess the humoral immune response to the BNT162b2 vaccine after allogeneic haematopoietic cell transplantation (HCT). METHODS: This is a prospective cohort study. The SARS-CoV-2 IgGII Quant (Abbott©) assay was performed 4 to 6 weeks after the second BNT162b2 vaccine for quantitative measurement anti-spike antibodies. RESULTS: The cohort included 106 adult patients. Median time from HCT to vaccination was 42 (range: 4 to 439) months. Overall, 15/106 (14%, 95% confidence interval (CI): 7% to 21%) were seronegative despite vaccination, 14/52 (27%, 95%CI: 19% to 35%) of patients on immunosuppression compared to only 1/54 (1.8%, 95%CI: 1% to 4%) of patients off immunosuppression (p=0.0002). The proportion of seronegative patients declined with time; it was 46% (6/13) during the first year, 12.5% (3/24) during the second year and 9% (6/69) beyond 2 years from transplant. Patients with acute graft-vs.-host disease (GVHD) (odds ratio (OR): 3.3, 95%CI: 0.97 to 11.1, P=0.06) and moderate to severe chronic GVHD (OR: 5.9, 95%CI: 1.2 to 29, P=0.03) were more likely to remain seronegative. Vaccination was well tolerated by most patients. Yet, 7% (7/106) reported that GVHD-related symptoms worsened within days following vaccination. CONCLUSION: A significant proportion of allogeneic HCT recipients receiving immunosuppression demonstrated an inadequate humoral response to the BNT162b2 vaccine. These patients should be recognised and instructed to take appropriate precautions. Recipients who were off immunosuppression had a humoral response that was comparable to that of the general population.

Compared with the general population, patients after allogeneic hematopoietic cell transplantation (alloHCT) are at higher risk to develop severe disease or die from COVID-19 1 . Immunosuppressive therapy and graft-vs.-host disease (GVHD) may abrogate the ability of transplanted patients to mount an adequate immune response to vaccines 2 . Immunocompromised patients were excluded from phase III trials evaluating SARS-CoV-2 vaccines 3 . Thus, data regarding the efficacy and safety of COVID vaccines after alloHCT are lacking. In the present study, we assessed the immune response of patients after alloHCT to the BNT162b2 vaccine (Pfizer-BioNTech) and identified patient-and treatment-related factors associated with humoral response in this population.

We conducted an observational prospective cohort study at the Rabin Medical Centre We classified patients according to serological status (positive vs. negative) 4 to 6 weeks after vaccination and used the likelihood ratio of the receiver-operating characteristics (ROC) curves to define the optimal cut-off for time from transplant. We used χ2 to compare variables on categorical scale and Mann-Whitney to compare medians. To explore factors associated with seronegativity at 4 to 6 weeks after vaccination, we applied univariable logistic regression with age, gender and haematological diagnosis, time from transplant, acute and chronic GVHD status and immunosuppression as putative predictors. Since recovery of the immune system after transplant is time dependent, we hypothesized that time from transplant predicts S-IgG titre levels after vaccination. To test this hypothesis, we used a linear J o u r n a l P r e -p r o o f regression model after transforming time in months and titre levels on a logarithmic scale to meet the linearity assumption of a linear model.

Our cohort included 106 adult patients (Table 1) We divided the cohort into patients who were transplanted within (60/106, 57%) vs. Titre levels in seropositive patients ranged between 60 and 80,000 AU/ml (median, 5319). In 60/106 (57%) of our patients, subsequent serological tests were available at J o u r n a l P r e -p r o o f a median follow up period of 4 (range: 2 to 6) months from the second vaccination.

Titre levels decreased by a median of 20% (range: 13% to 76%) per month and consequently 4/60 (7%) patients lost humoral response during the follow up period.

We found that time from transplant explained 16% of the variance in titre levels (y = 1.27x+1.36, R 2 = 0.16).

The vaccine was well tolerated by most patients. Until now, none of our patients developed COVID-19. No new cases of GVHD have been reported following vaccination. However, seven patients with chronic GVHD (mild, n=2; moderate, n=1; severe, n=4) reported that GVHD-related symptoms worsened within days following the first, second or both vaccines. Notably, one patient with severe chronic GVHD developed grade 4 steroid-refractory immune thrombocytopenia two weeks after the first vaccine.

The results of the present study show that the vast majority of alloHCT recipients mounted a positive S-IgG antibody response to the 2-dose BNT162b2 vaccine. Given the uncertainty regarding immunogenicity of vaccines in this immunocompromised population, these outcomes are remarkably good 5 . The results we obtained are considerably better than those reported in lung (18%), kidney (36.5%), liver (47.5%) and heart (50%) transplant recipients [6] [7] [8] [9] . Even after confining the analysis only to HCT recipients still receiving immunosuppression, the S-IgG antibody response proportion among HCT recipients (38/52, 73%) was still substantially superior to those reported after solid organ transplantation.

B-cell depleting monoclonal antibodies impair humoral response to vaccines, including the BNT1612b2 vaccine 10 . Yet, none of our patients received these agents during or after transplant and none received immunoglobulins.

Our study has several limitations; first, the study cohort is relatively small and any subgroup analysis is therefore exploratory in nature. Second, although we did not include patients with documented COVID-19 disease, yet we did not perform prevaccination serology testing. Therefore, we cannot exclude that patients with past J o u r n a l P r e -p r o o f unrecognized infection were included. Furthermore, the assay result was considered positive if S-IgG levels were ≥50 AU/ml. It should be kept in mind that this cut-off for positive antibody titre was established in healthy people. Studies are needed to determine whether this defined cut-off also applies to alloHCT recipients or whether this vulnerable population requires higher antibody titres for protection. Last, neither lymphocyte sub-population, nor T-cell immunity nor levels of neutralizing antibodies were measured in our study.

There are currently scarce data regarding the durability of the humoral response to SARS-CoV-2 vaccines in the healthy population and no data about its durability in HCT recipients 11 . Indeed, as part of the current study we intend to monitor S-IgG levels after 3, 6 and 12 months.

Although vaccination was usually well tolerated, it is worthy to note that several individuals reported on exacerbation of their GVHD symptoms, including one individual who developed severe immune thrombocytopenia. This is likely to have resulted from a robust vaccine-elicited immune response which may have fueled GVHD. These findings will need to be examined in subsequent studies. It is worthy to mention that vaccinations with Influenza and human papillomavirus were not associated with acute worsening of GVHD symptoms and GVHD did not develop de novo with these vaccines 12, 13 .

In conclusion, the proportion of non-responders to BNT162b2 vaccine among individuals off immunosuppression as well as those vaccinated >4.5 years after alloHCT and still receiving immunosuppression (6.5%) is similar to that of the general population. Therefore, routine serology testing after vaccination in this population is 10.9 HCT, hematopoietic cell transplantation; GVHD, graft versus host disease

Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study

A randomized trial of one versus two doses of influenza vaccine after allogeneic transplantation

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

SARS-CoV-2 IgG II quant

Vaccination post-allogeneic hematopoietic stem cell transplantation: what is feasible?

Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine

Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study

Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients -a prospective cohort study

Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients

Humoral serologic response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

Immune response following quadrivalent human papillomavirus vaccination in women after hematopoietic allogeneic stem cell transplant: a nonrandomized clinical trial

H1N1 in allogeneic stem cell recipients: courses of infection and influence of vaccination on graft-versushost-disease (GVHD)